REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Replimune Group, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.05+0.19 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $1.07B
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$84.11M
Long-term debt
Net debt
-$101.25M
After $185.36M of cash
Implied interest rate
10.48%
FY2026 interest ÷ average debt
Interest coverage
-47.1×
FY2026 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Replimune's annual report. Trading prices and yields need FINRA TRACE data.